The Relationship between Soluble Tumor Necrosis Factor-like Weak Inducer of Apoptosis Levels and Cardiac Functions in Peritoneal Dialysis Patients
- 1 September 2014
- journal article
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 12 (3) , 429-437
Abstract
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (sTWEAK) levels has been reported to be decreased in patients on hemodialysis (HD) and patients with heart failure. We aimed to study the relationship between sTWEAK levels and cardiac functions in peritoneal dialysis (PD) patients. This cross-sectional study was carried out on patients on chronic PD programs for more than three months. Patients aged under 18 or over 80 years, patients with overt cardiac disease, overt hypervolemia, active systemic infection, malignancy, peritonitis within the last month were excluded. The patient group was compared with the control group including healthy adults aged 24–61 years. Fifty-two PD patients were included in the study (mean age: 52.7±15.4 years; female/male ratio: 30/22). The corresponding data of the control group were 41.3±10.7 years and 17/14. There was no statistically significant difference between demographic parameters of the groups except age. The mean sTWEAK level of the patient and the control groups were similar (564±17 pcg/ml vs 535±126 pcg/ml, p=0.419). No correlation was detected between any of the demographic variables and sTWEAK levels. Among the echocardiographic parameters, only ejection fraction was found to be correlated negatively with sTWEAK levels. Patients with ischemic heart disease (IHD) and heart failure had significantly higher sTWEAK levels compared with the patients without these diseases. With linear regression analysis, only age and the presence of heart failure were found to be the independent determinants of sTWEAK levels. Level of sTWEAK is significantly high in PD patients with heart failure and IHD. sTWEAK may be a marker of cardiac functions in PD patients.Keywords
This publication has 27 references indexed in Scilit:
- Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?Journal Of Nephrology, 2012
- Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Considering TWEAK as a target for therapy in renal and vascular injuryCytokine & Growth Factor Reviews, 2009
- A Novel Role for Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) in the Development of Cardiac Dysfunction and FailureCirculation, 2009
- Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2009
- The Cytokine TWEAK Modulates Renal Tubulointerstitial InflammationJournal of the American Society of Nephrology, 2008
- Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease PatientClinical Journal of the American Society of Nephrology, 2008
- Kidney Disease and Cardiovascular RiskAnnual Review of Medicine, 2007
- Cytokine cooperation in renal tubular cell injury: The role of TWEAKKidney International, 2006